683 Capital Management’s Crescent Biopharma CBIO Stock Holding History

683 Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-194	Closed	-$45.7K	–	184
2023 Q4	$45.7K	Buy	+194	New	+$30.2K	﹤0.01%	226

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

683 Capital Management's CBIO Position: Q1 2024 in Review

683 Capital Management sold out of Crescent Biopharma (CBIO) in Q1 2024, closing a stake of 194 shares — an estimated $45.7K sold.

683 Capital Management first reported a position in CBIO in Q4 2023 and held it in 1 quarter. The position peaked at $45.7K in Q4 2023. 69 funds tracked by Wall St. Rank hold CBIO as of Q1 2024.

683 Capital Management reported no remaining Crescent Biopharma position as of Q1 2024 after selling out during the quarter.
683 Capital Management sold 194 Crescent Biopharma shares in Q1 2024, an estimated $45.7K.
683 Capital Management first reported a position in Crescent Biopharma in Q4 2023 and held it in 1 quarter.
683 Capital Management's Crescent Biopharma position peaked at $45.7K in Q4 2023.
69 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.